This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Rocket Stocks to Buy in October

Eli Lilly

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

For dividend seekers, pharmaceutical company Eli Lilly (LLY - Get Report) has a payout worth watching. Right now, the $56 billion big pharma firm pays a 4.06% dividend yield broken up into four quarterly 49-cent payouts. But that's not why this stock makes our list of Rocket Stock names; instead, we've got rising analyst expectations to thank for that.

>>5 Stocks Under $10 Set to Soar

Eli Lilly is no stranger to blockbuster drugs; the firm's patent list includes names like depression drug Cymbalta and ED pill Cialis, the types of recognizable names that are must-haves for a big pharma firm. But more important, a hefty pipeline of attractive late stage therapies bodes well for investors in the next few years. With the patent expiration cliff still causing a lot of anxiety in pharma investors (and in part spurring the huge dividend yields in the industry right now), that pipeline is quickly becoming more important than the existing drugs are.

And Eli Lilly has the wherewithal to continue developing those new offerings. The firm currently sports more than $11 billion in cash and investments on its balance sheet, offsetting around $5.5 billion in debt. With cash making up around 20% of LLY's market cap, the risks of investing in this name are hugely diminished as long as this stock can keep borrowing money at lower rates than its returns on capital.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
DIS $91.15 0.00%
IBM $121.04 0.00%
LLY $71.27 0.00%
PCLN $1,058.01 0.00%
V $70.42 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs